Overview
Portfolio
More
S32
San Jose, United States
S32 invests at the frontiers of technology, aiming to accelerate the discovery, development, and distribution of revolutionary technologies that improve the human condition. The firm backs companies across the entirety o...
Portfolio
102+
Employees
30+
Founded
2017
AUM
≈ $2.0B
Investment focus
Stages
No stages listed
Industries
No industries listedGeographic scope
United States
Fund details
Funds
Section 32 Fund 5-US
Vintage 2023 • $525.0M
Section 32 Fund 6-US
Vintage 2025 • $414.0M
Sources
S32
S32 invests at the frontiers of technology, aiming to accelerate the discovery, development, and distribution of revolutionary technologies that improve the human condition. The firm backs companies across the entirety of technology, leveraging deep experience in building iconic companies.
Portfolio
102+
Employees
30+
Founded
2017
AUM
≈ $2.0B
Funds
Section 32 Fund 5-US · Vintage 2023 • $525.0M
Section 32 Fund 6-US · Vintage 2025 • $414.0M
Stages
No stages listed
Industries
No industries listedGeographic scope
United States
Sources
Showing 24 of 89 matched portfolio companies
3EO Health utilizes patented 3TR amplification technology to deliver PCR-level sensitivity and specificity in respiratory diagnostics at a cost up to 70% lower than existing molecular tests. This preparation-free solution enables direct-to-test workflows, addressing the need for efficient and affordable diagnostic options in healthcare settings.
A2 Biotherapeutics develops Tmod™, a precision-targeting T cell therapy platform that distinguishes solid tumors from normal cells by exploiting specific gene losses unique to cancer cells. This approach addresses the challenge of effective treatment for solid tumors while minimizing damage to healthy tissue.
Funding: $352.9M
Rough estimate of the amount of funding raised
Funding: $352.9M
Rough estimate of the amount of funding raised
Alector uses a genetics‑first platform to identify protein pathways linked to neurodegeneration and develops CNS‑penetrant therapeutics—including monoclonal antibodies, engineered proteins, and gene‑delivery vectors—that clear toxic aggregates or modulate microglial activity. Its programs incorporate biomarker‑guided patient stratification and adaptive trial designs to accelerate development of disease‑modifying treatments for Alzheimer’s disease, frontotemporal dementia, and ALS.
Funding: $50.0M
Rough estimate of the amount of funding raised
Funding: $50.0M
Rough estimate of the amount of funding raised
AltPep is developing a highly-selective platform that utilizes custom-designed peptides to target and neutralize α-sheet toxic oligomers, which are early molecular triggers of amyloid diseases such as Alzheimer’s and Parkinson’s. Their approach enables early detection and disease-modifying treatment, aiming to alter the progression of these conditions before symptoms manifest.
Develops proprietary genomic editors that target the root causes of genetic diseases by selecting optimal editing tools based on disease-specific pathology. This approach enables the discovery and development of potentially curative genomic medicines, with a focus on liver and central nervous system disorders.
Funding: $230.6M
Rough estimate of the amount of funding raised
Funding: $230.6M
Rough estimate of the amount of funding raised
Aspen Neuroscience develops autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy specifically for Parkinson's disease, utilizing advanced stem cell biology and genomics. This approach addresses the degeneration of neurons in patients, aiming to restore lost function and improve quality of life.
Funding: $224.0M
Rough estimate of the amount of funding raised
Funding: $224.0M
Rough estimate of the amount of funding raised
Auris Health offers the MONARCH™ Platform, a robotic‑assisted bronchoscopy system that provides precise, 6‑degree‑of‑freedom control of a flexible bronchoscope for navigating to peripheral lung lesions. Integrated real‑time navigation software fuses CT imaging with positional data to guide biopsies and therapeutic interventions with sub‑centimeter accuracy, improving tissue acquisition rates while monitoring safety parameters.
Autobahn Therapeutics is developing orally administered small molecule prodrugs using a brain-targeting chemistry platform to create tailored therapies for neuropsychiatric and neuroimmunologic disorders. Their approach focuses on restoring brain health by leveraging validated human biology and biomarker-driven development to address the progressive nature of these debilitating conditions.
Funding: $214.5M
Rough estimate of the amount of funding raised
Funding: $214.5M
Rough estimate of the amount of funding raised
Autoscience Institute develops AI-powered tools designed to automate the mechanics of scientific discovery for research teams. Their platform includes Mira for accelerating applied machine learning research through automated architecture discovery and Carl for automated academic research, including paper analysis and result generation. These systems allow researchers to focus on breakthroughs by handling complex, time-consuming tasks in the knowledge mapping process.
Basecamp Research provides a cloud‑based platform that unifies the research workflow, enabling users to design studies, recruit participants, manage consent, and capture data through a drag‑and‑drop builder. The system offers secure, GDPR/CCPA‑compliant storage, real‑time analytics with built‑in statistical tools, and API integration for exporting results to external pipelines.
Funding: $85.9M
Rough estimate of the amount of funding raised
Funding: $85.9M
Rough estimate of the amount of funding raised
BigHat Biosciences utilizes a machine learning-guided antibody design platform, Milliner, which integrates synthetic biology and high-speed wet lab processes to rapidly synthesize and characterize recombinant antibodies. The company focuses on developing safer and more effective antibody therapies for patients with challenging diseases, enhancing treatment options in the biopharmaceutical landscape.
Funding: $139.3M
Rough estimate of the amount of funding raised
Funding: $139.3M
Rough estimate of the amount of funding raised
BloomText is a HIPAA-compliant messaging platform that enables healthcare providers to securely communicate with patients and staff via text, images, and documents without requiring app downloads. This solution enhances patient engagement and operational efficiency by streamlining communication workflows and facilitating real-time information sharing.
Brightside Health is a telemedicine platform that combines personalized psychiatry and clinically-proven therapy to provide targeted treatment for anxiety, depression, and other mental health conditions. By utilizing data-driven assessments and tailored care plans, the platform enables patients to receive effective support and medication management from licensed professionals within days.
Funding: $109.4M
Rough estimate of the amount of funding raised
Funding: $109.4M
Rough estimate of the amount of funding raised
Provides cloud-based cancer diagnostic services using whole-genome sequencing and AI-driven algorithms to detect minimal residual disease (MRD) in blood samples. This approach enables faster results, requires less blood, and offers a comprehensive view of tumor genetic landscapes, improving early detection and monitoring for pharmaceutical and diagnostic organizations.
Celsius Therapeutics develops precision medicines utilizing genomic and proteomic data to create targeted therapies for patients with cancer and autoimmune diseases. By focusing on the underlying biological mechanisms of these conditions, the company aims to improve treatment efficacy and patient outcomes.
Founded 2018
Funding: $15.0B
Rough estimate of the amount of funding raised
Funding: $15.0B
Rough estimate of the amount of funding raised
Character is a precision medicine company focused on macular degeneration and primary open-angle glaucoma, utilizing clinical genomic databases and machine learning to identify genetic drivers of disease progression. By characterizing patient subtypes, Character aims to develop targeted therapies for conditions that currently have limited treatment options.
Funding: $24.0M
Rough estimate of the amount of funding raised
Funding: $24.0M
Rough estimate of the amount of funding raised
Coinbase is a cryptocurrency exchange and wallet platform that enables users to buy, sell, and securely store digital currencies using blockchain technology. It provides a user-friendly interface for both merchants and consumers, facilitating seamless transactions in the growing digital currency market.
Funding: $563.1M
Rough estimate of the amount of funding raised
Funding: $563.1M
Rough estimate of the amount of funding raised
Culture Biosciences develops cloud-connected bioreactors that enable real-time experiment design, monitoring, and data analysis for bioprocess development. Their technology allows companies to optimize cell culture processes and accelerate product development without the constraints of traditional lab setups.
Funding: $101.6M
Rough estimate of the amount of funding raised
Funding: $101.6M
Rough estimate of the amount of funding raised
Deel is a payroll and compliance platform that enables companies to hire, onboard, and manage employees and contractors globally without establishing local legal entities. It addresses the complexities of international payroll, compliance with local labor laws, and the need for streamlined HR operations across diverse jurisdictions.
Funding: $300.0M
Rough estimate of the amount of funding raised
Funding: $300.0M
Rough estimate of the amount of funding raised
Delve Bio provides the Delve Detect test, a metagenomic sequencing (mNGS) solution for diagnosing CNS infections like meningitis and encephalitis. This culture-independent test rapidly identifies bacteria, viruses, fungi, and parasites from cerebrospinal fluid using a comprehensive genetic database. The service offers a higher diagnostic yield and faster turnaround time compared to conventional infectious disease testing methods.
Dialpad provides a cloud‑native platform that consolidates voice, video, messaging and contact‑center functions into a single application. The service uses AI to transcribe calls in real time, generate summaries and actionable insights, and automate routine workflows such as scheduling and refunds across multiple channels. Integrated CRM connectors, AI coaching tools and enterprise‑grade security enable mid‑size to large organizations to streamline communications and improve agent productivity.
Funding: $50.0M
Rough estimate of the amount of funding raised
Funding: $50.0M
Rough estimate of the amount of funding raised
Digg is a community platform that lets users join interest‑based groups where content is surfaced through peer up‑votes and recommendations rather than algorithmic feeds. The service includes transparent moderation with publicly documented rules and visible enforcement, and offers native iOS and Android apps with secure sign‑in via Google, Apple or email. An invite‑only beta ensures a controlled rollout for high‑quality early adopters.
Ema utilizes a Generative Workflow Engine™ and a library of AI agents to automate complex workflows in HR, customer support, and data management, enhancing productivity across various enterprise roles. By integrating with hundreds of applications and employing a proprietary EmaFusion™ model, Ema ensures data accuracy and compliance while reducing operational costs.
Funding: $75.0M
Rough estimate of the amount of funding raised
Funding: $75.0M
Rough estimate of the amount of funding raised
The startup offers a DNA testing kit that utilizes genetic marker analysis to provide dog owners with essential health information, including breed identification and insights into genetic disease risks. By using a simple cheek swab, pet owners can gain valuable knowledge about their dog's health and hereditary traits, enhancing overall pet wellness.
Funding: $75.0M
Rough estimate of the amount of funding raised
Funding: $75.0M
Rough estimate of the amount of funding raised
Showing 12 of 13 unmatched portfolio companies